RecruitingPhase 2NCT07141329
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures
Sponsor
Supernus Pharmaceuticals, Inc.
Enrollment
100 participants
Start Date
Jul 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called SPN-817 for people with focal onset seizures. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSPN-817
SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07141329